Trials / Completed
CompletedNCT01969656
Safety Study of an Oral Vitamin D Analog in Postmenopausal Women
A Phase 1B, Double-Blind, Placebo-Controlled, Calcitriol Active-Controlled, Daily-Dose, Escalating-Dose, Safety and Tolerance Study of 2MD Soft Gel Capsules in Normal Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Deltanoid Pharmaceuticals · Industry
- Sex
- Female
- Age
- 45 Years – 80 Years
- Healthy volunteers
- —
Summary
Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2MD | |
| DRUG | Calcitriol | |
| DRUG | Placebo |
Timeline
- Primary completion
- 2004-06-01
- First posted
- 2013-10-25
- Last updated
- 2017-07-27
Source: ClinicalTrials.gov record NCT01969656. Inclusion in this directory is not an endorsement.